Rise in demand for early diagnosis is driving the genomics personalized health market size. Personalized genomics is essential for early screening, diagnosis, and individualized treatment as 80% of rare diseases have genetic origins.

WILMINGTON, Del., July 26, 2024 /PRNewswire/ -- The global genomics personalized health market is projected to attain a valuation of US$ 33 billion by 2034, advancing at a CAGR of 12.2% in the forthcoming decade, as per a recent report published by Transparency Market Research.

The genomics personalized health market is rapidly evolving, fueled by cutting-edge technological advancements and an increasing focus on individualized healthcare. One of the key drivers of this market is the advent of next-generation sequencing (NGS) technologies, which have drastically reduced the cost and time required for sequencing the human genome.

This has made genomic data more accessible, enabling healthcare providers to tailor treatments to the genetic profiles of individual patients. The market is also benefitting from advancements in bioinformatics and computational biology. These fields are essential for managing and interpreting the vast amounts of data generated by genomic studies.

Access Your Sample PDF Brochure:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=12197 

Artificial intelligence (AI) and machine learning (ML) are being increasingly integrated into genomics, enhancing the ability to identify genetic markers for diseases, predict patient responses to treatments, and discover new therapeutic targets. In terms of market trends, there is a growing emphasis on preventive healthcare and early disease detection.

Personalized health genomics plays a crucial role in these areas by identifying individuals at high risk for certain conditions, allowing for early interventions and lifestyle modifications. The rise of direct-to-consumer (DTC) genetic testing is another notable trend.

Key Takeaways from the Market Study

• The global genomics personalized health market is poised to total US$ 10.2 billion in 2024.
• From 2024 to 2034, the market for genomics personalized health is slated to expand 3.2x.
• By technology, NGS platforms are expected to be relied upon extensively to offer genomics personalized health services.
• Genomics personalized health services are likely to be utilized mostly for oncology testing.
• Diagnostic centers to be primary sites for availing genomics personalized health services.

Key Drivers and Trends

• To enhance therapeutic applications, substantial funding is being directed to genomic research from the public and private sectors. R&D is particularly strong in fields such as population genomics, pharmacogenomics, precision oncology, and genetic disease diagnostics.
• Genomic medicine is being advanced by large-scale sequencing projects such as the Asia 100K and the U.K.'s 100K Genomes Project. To jointly create genetic tests and solutions, biopharma businesses, technology companies, and diagnostic labs are increasingly forming alliances.
• These activities are augmenting the genomics personalized health market revenue. Besides this, various pharmaceutical companies are contributing to genomic data-sharing programs.
• In December 2021, Seven Bridges Genomics, a bioinformatics ecosystem provider, announced the formation of a new subsidiary, the Unified Patient Network (UPN), to facilitate clinical research and collaboration between participating health systems and biopharma companies with a focus on advancing precision medicine and improving patient care.

Download PDF Sample:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=12197

Genomics Personalized Health Market Report Scope:

Regional Analysis

• There is likely to be significant progress in the genomics personalized health ecosystem in North America. Demand is expected to run on the back of wider budget allocation on healthcare spending brought about by growing awareness about key health conditions.
• Pharmaceutical and healthcare companies are increasing their inroads in the North American market, as the availability of adequate research facilities to promote genomics and genetics are inclining.
• Since personalized medicine is currently preferred for treating various types of illnesses, medication discovery and research on specific illnesses are interrelated. Various companies are developing customized diagnosis products.

Competitive Landscape

Key players operating in the genomics personalized health market landscape are offering robust precision medicine genomics services and programs that leverage predictive analytics to provide targeted treatment regimens.

These services help prevent and treat diseases at their earliest stages when they are most treatable. Some prominent genomics personalized health providers are:

• QIAGEN
• Illumina Inc.
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories Inc.
• Hoffmann-La Roche AG
• Lonza Group
• Invitae Corp
• Genetic Technologies Limited
• Interleukin Genetics Inc.
• Eastern Biotech and Life Sciences
• DNA Genotek Inc.
• UBiome Inc.
• XCode Life Sciences Private Limited
• Proove Genomics

Companies like 23andMe and AncestryDNA have popularized personal genomics, enabling consumers to access their genetic information and gain insights into their ancestry, traits, and health predispositions. Strategic partnerships and collaborations are shaping the market landscape.

Pharmaceutical companies are partnering with genomic research firms to develop targeted therapies, while technology companies are collaborating with healthcare providers to integrate genomic data into electronic health records (EHRs). These collaborations are fostering innovation and expanding the applications of genomic technologies.

Key Market Developments

• Illumina Inc. acquired Fluent BioSciences in July 2024. This acquisition marks a significant milestone in the former's multiomics growth strategy. The acquisition has enabled Illumina to utilitze Fluent's innovative and flexible single-celled approach to multiomoics.
• In September 2021, Invitae Corp., a medical genetics company, announced the acquisition of Ciitizen, a consumer health technology company. This acquisition will expand the consumer genomics product portfolio of Invitae Corp.

Key Segments Covered

By Technology

• NGS Platform
• RT-PCR
• Microarray
• Genetic Analyzer
• Others

By Test Type

• Oncology Testing
• Infectious Disease Testing
• Orphan Disease Testing
• Autoimmune Disease Testing
• Obstetrics Testing
• Others

By End User

• Academic & Research Institutes
• Diagnostic Centers
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Buy this Premium Research Report:
https://www.transparencymarketresearch.com/checkout.php?rep_id=12197&ltype=S 

More Trending Reports by Transparency Market Research –

• Dental Syringe Market- The global dental syringe industry was valued at US$ 343.4 Mn in 2021 and it is projected to grow at a CAGR of 5.1% from 2022 to 2031 and reach more than US$ 577.8 Million by the end of 2031.
• Pediatric Perfusion Products Market - The global pediatric perfusion products industry was valued at US$ 147.0 Mn in 2021 and it is projected to advance at a CAGR of 7.3% from 2022 to 2031 and reach more than US$ 294.6 Million by the end of 2031.
• Lip Augmentation Market – The global lip augmentation market is expected to grow at a CAGR of 8.4% from 2024 to 2034.
• Laboratory Robotics Market – The global laboratory robotics market is expected to grow at a CAGR of 6.6% from 2024 to 2034.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com   
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn | Twitter | Blog | YouTube

Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/genomics-personalized-health-market-to-reach-us-33-billion-by-2034-driven-by-advances-in-next-generation-sequencing---transparency-market-research-inc-302207592.html

SOURCE Transparency Market Research